Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Blood|February 4, 2010
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik, Javier Bolaños-Meade, Marianna Zahurak, et al.
Blood|April 21, 2023
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemiaAmy E DeZern, Marianna Zahurak, Heather J Symons, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 6, 2024
Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatmentEmily Symington, Savita Rangarajan, Will Lester, et al.
Blood Advances|September 8, 2019
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70Philip H Imus, Hua-Ling Tsai, Leo Luznik, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 26, 2024
Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia ABrian R Long, Tara M Robinson, Jonathan R S Day, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade, Elizabeth Garrett-Mayer, Leo Luznik, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2018
Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationYvette L Kasamon, Ephraim J Fuchs, Marianna Zahurak, et al.
Blood Advances|February 15, 2018
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamideShannon R McCurdy, Mei-Jie Zhang, Andrew St Martin, et al.
Leukemia & Lymphoma|August 22, 2015
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamideLindsey R Lombardi, Christopher G Kanakry, Marianna Zahurak, et al.
Pageof 15